The role of surgery in high risk and advanced prostate cancer: A narrative review.


Journal

Turkish journal of urology
ISSN: 2149-3235
Titre abrégé: Turk J Urol
Pays: Turkey
ID NLM: 101643563

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 19 10 2020
accepted: 21 10 2020
pubmed: 18 11 2020
medline: 18 11 2020
entrez: 17 11 2020
Statut: ppublish

Résumé

Patients with high-risk and advanced prostate cancer require safe and efficacious therapies likely to offer a survival advantage while minimizing the treatment-related toxicities. Improvements in the surgical technology, diagnostic modalities, radiological staging, and risk stratification have made surgery for high-risk and advanced prostate cancer a safe and feasible option. In this review, we outline the role of radical prostatectomy in high-risk localized, locally advanced, and metastatic prostate cancer. We overview available data evaluating the use of surgery in the context of a multi-modal approach and highlight ongoing trials in this area. Furthermore, the role of surgery as a non-systemic modality for metastasis-directed therapy (MDT) is also described. Emerging imaging modalities enabling more accurate staging and longer follow-up of clinical trials for prognostic endpoints are anticipated to help identify patient cohorts and treatment strategies, where the use of surgical treatments is likely to provide oncological benefits and acceptable toxicity.

Identifiants

pubmed: 33201799
pii: tud.2020.20475
doi: 10.5152/tud.2020.20475
pmc: PMC8057352
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

S56-S64

Références

Lancet. 2002 Jul 13;360(9327):103-6
pubmed: 12126818
Eur Urol Oncol. 2018 May;1(1):46-53
pubmed: 31100228
Eur Urol. 2019 Jan;75(1):176-183
pubmed: 30301694
Curr Opin Urol. 2020 Jan;30(1):90-97
pubmed: 31724996
Scand J Urol. 2018 Oct - Dec;52(5-6):313-320
pubmed: 30585526
Hum Pathol. 2018 May;75:159-166
pubmed: 29447924
Urology. 2016 Sep;95:11-5
pubmed: 26790588
J Clin Oncol. 2015 Jul 1;33(19):2143-50
pubmed: 25691677
Eur Urol. 2019 Oct;76(4):493-504
pubmed: 30391078
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
JAMA Oncol. 2016 Mar;2(3):348-57
pubmed: 26606329
J Clin Oncol. 2009 Aug 20;27(24):3916-22
pubmed: 19620493
Eur Urol. 2015 Jun;67(6):1028-1038
pubmed: 25301760
World J Urol. 2021 Feb;39(2):317-326
pubmed: 31955223
J Clin Oncol. 2017 Nov 1;35(31):3566-3574
pubmed: 28930493
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):259-264
pubmed: 28349979
BMJ Open. 2021 Feb 25;11(2):e042953
pubmed: 33632752
Eur Urol. 2014 Jun;65(6):1058-66
pubmed: 24290503
Eur Urol. 2010 Jul;58(1):1-7; discussion 10-1
pubmed: 20299147
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
pubmed: 2673568
Cancer. 2011 Jul 1;117(13):2883-91
pubmed: 21692049
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Lancet. 2020 Oct 31;396(10260):1422-1431
pubmed: 33002431
Eur Urol. 2014 Jan;65(1):124-37
pubmed: 24207135
BJU Int. 2017 Nov;120(5B):E8-E20
pubmed: 28581205
BJU Int. 2005 Apr;95(6):751-6
pubmed: 15794776
J Oncol Pract. 2018 Oct;14(10):580-587
pubmed: 30312560
Eur Urol Oncol. 2018 Jun;1(2):143-148
pubmed: 31100238
Eur Urol Focus. 2017 Dec;3(6):646-649
pubmed: 28753877
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464
J Urol. 2006 Sep;176(3):991-5
pubmed: 16890678
Eur Urol. 2007 Oct;52(4):1058-65
pubmed: 17418938
Eur Urol. 2019 Mar;75(3):419-422
pubmed: 30553614
World J Urol. 2019 Nov;37(11):2343-2353
pubmed: 30706122
Eur Urol. 2020 Dec;78(6):779-782
pubmed: 32624281
BMJ. 2014 Feb 26;348:g1502
pubmed: 24574496
Eur Urol. 2020 May;77(5):614-627
pubmed: 32146018
Eur Urol Focus. 2019 Mar;5(2):159-161
pubmed: 30642810
J Clin Oncol. 2020 Sep 10;38(26):3042-3050
pubmed: 32706639
Eur Urol. 2019 Apr;75(4):552-555
pubmed: 30420255
Ther Adv Urol. 2019 Jan 08;11:1756287218815793
pubmed: 30671137
Cancer. 2006 Sep 15;107(6):1265-72
pubmed: 16900523
Eur Urol. 2018 Jun;73(6):870-876
pubmed: 29395502

Auteurs

Chloe Sheila Dayan Roy (CSD)

Department of Urology, Freeman Hospital, Newcastle-upon-Tyne, UK.

Ashwin Sachdeva (A)

Department of Urology, Freeman Hospital, Newcastle-upon-Tyne, UK.

Gokul Vignesh Kandaswamy (GV)

Department of Urology, Morriston Hospital, Swansea, UK.

Bhavan Prasad Rai (BP)

Department of Urology, Freeman Hospital, Newcastle-upon-Tyne, UK.

Classifications MeSH